RCM - R1 RCM updates guidance to higher end post Cloudmed acquisition

In its guidance update call, R1 RCM (NASDAQ:RCM) updated its 2022 guidance post the Cloudmed acquisition which closed on June 21, 2022 wherein R1 issued 135.9M shares to Cloudmed shareholders. Post the acquisition, the company sees strong cash generation post-close and year-end net leverage of 2.5-3.0x. The company guides Q2 revenue of $390-392M; Q2 adjusted EBITDA is seen at $85-87M. The company expects Q3 and Q4 adj. EBITDA to ramp higher, reflecting Cloudmed plus typical 2H ramp. It raises FY22 revenue outlook to $1.85-1.87B from $1.66-1.70B prior guidance. while adj. EBITDA guidance raised to $470-480M from $385-405M prior guidance. 2022 guidance range: The company also provided financial outlook post 2022:

For further details see:

R1 RCM updates guidance to higher end post Cloudmed acquisition